<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Auchus, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2650775471"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>More than 90 percent of cases of congenital adrenal hyperplasia (CAH) result from impaired conversion of 17-hydroxyprogesterone to 11-deoxycortisol [<a href="#rid1">1</a>]. This conversion is mediated by 21-hydroxylase, or in current terminology, P450 21A2, which is encoded by the <em>CYP21A2</em> gene. Inadequate 21-hydroxylase activity results in both adrenal insufficiency due to impaired cortisol biosynthesis and adrenal hyperandrogenism  (<a class="graphic graphic_figure graphicRef81907" href="/z/d/graphic/81907.html" rel="external">figure 1</a>).</p><p>Patients with "classic" or the more severe form of CAH due to 21-hydroxylase deficiency (21OHD) present during the neonatal period and early infancy with adrenal insufficiency or as toddlers with virilization. Females have atypical genitalia.</p><p>The treatment of adults with classic CAH due to 21OHD will be reviewed here. The genetics, clinical manifestations, and diagnosis of classic 21OHD and the management of classic 21OHD in infants and children are discussed elsewhere. The diagnosis and treatment of nonclassic 21OHD in adults are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p></p><p></p><p class="headingAnchor" id="H932630112"><span class="h1">TRANSITION FROM PEDIATRIC TO ADULT CARE</span></p><p class="headingAnchor" id="H681331238"><span class="h2">Establishing care</span><span class="headingEndMark"> — </span>For individuals with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD), the transition from pediatric to adult care should be carefully planned to help prepare patients for issues that arise postpuberty. In both children and adults with classic 21OHD, management of adrenal insufficiency and adrenal hyperandrogenism are central goals of treatment. However, adults have additional health concerns including sexual function and fertility [<a href="#rid2">2</a>]. Adults with classic 21OHD also face potential long-term complications of both the disease itself and chronic glucocorticoid therapy, such as obesity, adrenal rest tumors, bone loss, and impaired quality of life [<a href="#rid2">2-5</a>]. Ideally, adults with classic 21OHD should have interdisciplinary care that includes an endocrinologist and a reproductive specialist with expertise in CAH, as well as a urologist (for males) or gynecologist (for females).</p><p>When possible, engagement in adult care should begin several years prior to cessation of pediatric care [<a href="#rid2">2</a>]. This overlap enables the gradual introduction of issues and concerns specific to adult care and maintains contact with familiar pediatric providers while relationships with adult providers are established.</p><p class="headingAnchor" id="H2940864579"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>During the transition to adult care, adrenal hormone treatment regimens should be reassessed. Patient education and safety should be reinforced and remain cornerstones of treatment. Additional assessments reflect the overarching goal of optimizing reproductive health during adulthood.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid and mineralocorticoid treatment regimens</strong> – All adults with classic 21OHD require continued glucocorticoid therapy, and most require continued mineralocorticoid therapy. Therefore, in adults, a distinction between "salt wasting" versus simple virilizing" subtypes of classic 21OHD should be avoided. This distinction is important for newborns with classic 21OHD, but it is irrelevant for adults and often encourages withholding of vital therapies. Nonetheless, adrenal hormone dosing requirements often change with age and cessation of growth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid therapy</strong> – In adults with classic 21OHD, glucocorticoid therapy is required to treat cortisol deficiency, optimize reproductive function and, in females, minimize hyperandrogenic symptoms. <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a> therapy can achieve these goals and imparts lower risk of long-term complications than longer-acting glucocorticoids. (See <a class="local">'Goals of adrenal hormone therapy'</a> below and <a class="local">'Hydrocortisone (preferred glucocorticoid)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mineralocorticoid therapy</strong> – In virtually all adults with classic 21OHD, continued <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> therapy is needed to treat mineralocorticoid deficiency. However, dosing requirements are usually lower than in children or adolescents. (See <a class="local">'Mineralocorticoid replacement'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient counseling</strong> – Patient education and engagement in self-care are critical for treatment adherence and safety [<a href="#rid6">6</a>]. Extensive patient counseling is essential to help prepare patients for both acute and long-term management issues. (See <a class="local">'Patient safety and counseling'</a> below and <a class="local">'Monitoring for long-term complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of patient-centered goals and concerns</strong> – In adults with classic 21OHD, glucocorticoid therapy is tailored in part to achieve individualized patient goals. We ask all patients about their long-term goals for reproductive health and fertility. We ask females about their goals for management of hyperandrogenic symptoms (eg, unwanted androgen-dependent terminal hair growth, acne). (See <a class="local">'Fertility and reproductive health'</a> below and <a class="local">'Additional intervention for persistent symptoms'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling</strong> – Genetic counseling should be provided during adolescence and again during the transition to adult care to help inform decisions about fertility [<a href="#rid2">2</a>]. (See <a class="local">'Genetic counseling for all adults'</a> below and  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testicular ultrasound (males)</strong> – For males, a testicular ultrasound should be performed to evaluate for testicular adrenal rest tumors (TARTs) [<a href="#rid2">2</a>]. Thereafter, the frequency of monitoring depends in part on laboratory and physical examination findings. (See <a class="local">'Screening for testicular adrenal rest tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menstrual history and gynecologic examination (females)</strong> – For females, a genitourinary examination should be performed (if not performed previously during adolescence), and menstrual history should be assessed. In postpubertal females with classic 21OHD, central goals of management are to optimize menstrual and sexual function. (See <a class="local">'Females'</a> below.)</p><p></p><p class="headingAnchor" id="H3014325810"><span class="h1">CONTINUED ADRENAL HORMONE THERAPY</span></p><p class="headingAnchor" id="H4276957328"><span class="h2">Goals of adrenal hormone therapy</span><span class="headingEndMark"> — </span>In adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD), the two major goals of adrenal hormone therapy are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Provide adequate glucocorticoid and mineralocorticoid replacement, as with any form of adrenal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Attenuate the production of adrenal-derived steroids through partial suppression of both corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion.</p><p></p><p>Adequate suppression of CRH and ACTH can be difficult to achieve without supraphysiologic glucocorticoid dosing, which confers long-term risks of bone loss, cardiometabolic disease, and other clinical manifestations of iatrogenic Cushing syndrome. Therefore, careful dose titration is needed to find the lowest glucocorticoid dose that achieves both treatment goals. (See <a class="local">'Monitoring and dose adjustment'</a> below.)</p><p class="headingAnchor" id="H921458608"><span class="h2">Glucocorticoid therapy for all patients</span><span class="headingEndMark"> — </span>In adults with classic 21OHD, limited data are available to guide selection of a specific glucocorticoid regimen. The approach to management detailed below is guided primarily by clinical experience and largely consistent with the Endocrine Society guidelines [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1522511805"><span class="h3">Selection of regimen</span><span class="headingEndMark"> — </span>For adults with classic 21OHD, we suggest the short-acting glucocorticoid <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>. Among options for glucocorticoid treatment, hydrocortisone is the least likely to cause cushingoid complications. However, it is less convenient than other synthetic glucocorticoids as it is typically administered in multiple daily doses. (See <a class="local">'Transition to adult dosing'</a> below.)</p><p>Adolescents with classic 21OHD may use longer-acting glucocorticoid regimens to promote treatment adherence. When such individuals establish adult care, we encourage transition to <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> therapy.</p><p>If an individual anticipates substantial difficulty adhering to three times daily <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>, or if adherence proves difficult after a trial of hydrocortisone therapy, we substitute a longer-acting glucocorticoid, typically <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>. Where available, modified-release hydrocortisone is a reasonable alternative. (See <a class="local">'Longer-acting glucocorticoids for adherence challenges'</a> below and <a class="local">'Modified-release hydrocortisone (limited availability)'</a> below.)</p><p>In adults with severe 21OHD who do not achieve adequate adrenal androgen suppression on <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> alone, we add a small dose of a longer-acting glucocorticoid at bedtime to suppress overnight ACTH secretion. (See <a class="local">'Combined regimens for persistent hyperandrogenism'</a> below.)</p><p class="headingAnchor" id="H2215385875"><span class="h3">Hydrocortisone (preferred glucocorticoid)</span></p><p class="headingAnchor" id="H4098966719"><span class="h4">Transition to adult dosing</span><span class="headingEndMark"> — </span>For adults with classic 21OHD, a typical regimen is <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> 15 to 30 mg daily administered in three divided doses  (<a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">table 1</a>). The largest dose is taken in the morning upon waking, and progressively smaller doses are taken late morning/midday and late afternoon/early evening (eg, 15, 5, and 2.5 mg). The total daily dose depends on both the patient's body size and severity of 21OHD. Individuals with larger body size generally require higher hydrocortisone doses for sufficient cortisol replacement, and those with more severe 21OHD require higher doses for adequate adrenal androgen suppression.</p><p>In contrast to other types of adrenal insufficiency, adequate treatment of classic 21OHD usually requires three rather than two daily doses of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>. The third dose helps to limit the overnight rise in ACTH secretion that promotes adrenal androgen production. Hydrocortisone administration three times daily usually provides sufficient suppression of adrenal steroids without imparting clinical manifestations of glucocorticoid excess.</p><p class="headingAnchor" id="H1927379546"><span class="h4">Monitoring and dose adjustment</span><span class="headingEndMark"> — </span>During the transition to adult care or titration of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> therapy, adults with classic 21OHD should be evaluated every three to four months through both clinical and laboratory assessments. Adults who are on stable hydrocortisone regimens should be seen at least once annually.</p><p>The goal of dose titration is to achieve the lowest <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> dose that provides both adequate cortisol replacement and sufficient suppression of adrenal steroid production.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical assessment</strong> – Clinical assessments include measurement of body weight, blood pressure, and heart rate. Patients should be queried about sleep quality, changes in body weight and appetite, energy, cognition and concentration, daytime somnolence, and nausea. Signs and symptoms that suggest undertreatment include weight loss, weakness, hypotension, and fatigue. Signs and symptoms of overtreatment include body weight gain, impaired sleep, increased blood pressure, and edema. Signs of chronic overtreatment include dermal atrophy, bruising, proximal muscle weakness, purple striae, and other manifestations of Cushing syndrome. (See  <a class="medical medical_review" href="/z/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a>.)</p><p></p><p class="bulletIndent1">In addition, females should be assessed for signs of androgen excess (eg, acne, hirsutism, oily skin, sweating) at each visit.</p><p></p><p class="bulletIndent1">In males, testicular atrophy on examination suggests chronic gonadotropin suppression from adrenal-derived androgens and thus indicates glucocorticoid undertreatment. Testicular examinations are performed primarily to evaluate for testicular adrenal rest tumors (TARTs). (See <a class="local">'Screening for testicular adrenal rest tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory assessment</strong> – Blood draws for laboratory testing are best performed consistently at the same time of day (ideally in the morning) due to circadian variation in these levels. Routine laboratory measurements should include serum concentrations of the following [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Androstenedione (generally considered the most relevant biomarker)</p><p class="bulletIndent2"><span class="glyph">•</span>Testosterone</p><p class="bulletIndent2"><span class="glyph">•</span>Sex-hormone binding globulin (SHBG; used to calculate free and bioavailable testosterone)</p><p class="bulletIndent2"><span class="glyph">•</span>Follicle-stimulating hormone (FSH) and luteinizing hormone (LH; routinely in males and in females with oligo- or amenorrhea)</p><p></p><p class="bulletIndent1">Serum 17-hydroxyprogesterone also may be useful for detecting glucocorticoid overtreatment, but routine measurement is not essential for treatment monitoring in adults. Given the limitations of current therapy and the adverse consequences of supraphysiologic glucocorticoid dosing, target laboratory values for titrating glucocorticoid therapy cannot be uniformly established for adults with 21OHD. In undertreated males and all females with classic 21OHD, the most abundant circulating androgen is not testosterone but rather 11-ketotestosterone, which is only measured in certain reference and research laboratories [<a href="#rid8">8</a>]. The following guidance is based on clinical experience and consensus guidelines [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Males</strong> – In males, glucocorticoid therapy should be titrated to maintain testicular function, which generally requires the serum androstenedione level at or near the upper limit of the normal range. In contrast, normalization of 17-hydroxyprogesterone indicates glucocorticoid overtreatment. Gonadotropin (FSH and LH) levels should be maintained in the normal range; suppressed gonadotropins and/or an androstenedione/testosterone ratio &gt;1 indicate inadequate suppression of adrenal androgen production. Such findings should prompt both consideration of glucocorticoid therapy intensification and additional evaluation for TARTs with testicular examination and/or ultrasound. (See <a class="local">'Screening for testicular adrenal rest tumors'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Females</strong> – In females not pursuing fertility, glucocorticoid therapy should be titrated to achieve normalized menstrual function and individualized goals for suppression of hyperandrogenic symptoms (eg, unwanted androgen-dependent terminal hair growth or acne). These goals are usually achieved with androgen (androstenedione, testosterone) levels at or near the upper limit of the normal range. Testosterone and androstenedione should <strong>not</strong> be suppressed below the normal range, as this indicates overt glucocorticoid overtreatment. A normalized 17-hydroxyprogesterone level similarly indicates glucocorticoid overtreatment.</p><p></p><p class="bulletIndent2">In females pursuing fertility, treatment goals differ and are reviewed below. (See <a class="local">'Fertility'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose adjustment</strong> – We adjust the <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> dose in 2.5 to 5 mg increments as needed based on evidence of over- or undertreatment. If signs or symptoms of cortisol deficiency are evident throughout the day, we preferentially increase the morning dose. If additional suppression of adrenal androgens is needed, we empirically increase the doses throughout the day; increasing more than one dose is often necessary for sufficient adrenal steroid suppression.</p><p></p><p class="bulletIndent1">Increased evening doses of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> may be limited by impaired sleep. If impaired sleep or other evidence of glucocorticoid excess develops, or if adequate adrenal androgen suppression cannot be achieved on a total daily hydrocortisone dose ≤30 to 35 mg, combination therapy may be helpful. (See <a class="local">'Combined regimens for persistent hyperandrogenism'</a> below.)</p><p></p><p class="bulletIndent1">In females with persistent signs of hyperandrogenism despite normalized serum androgen levels, we pursue alternative treatment strategies. (See <a class="local">'Additional intervention for persistent symptoms'</a> below.)</p><p></p><p class="headingAnchor" id="H1014118477"><span class="h3">Alternative regimens</span></p><p class="headingAnchor" id="H3255297210"><span class="h4">Combined regimens for persistent hyperandrogenism</span><span class="headingEndMark"> — </span>In adults in whom adequate adrenal steroid suppression cannot be achieved with standard <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> regimens, we suggest combination therapy [<a href="#rid9">9</a>]. Combination therapy entails typical cortisol replacement doses of hydrocortisone (eg, 10 to 25 mg daily) during the day and a very small dose of a longer-acting glucocorticoid at bedtime (eg, 1 to 2 mg <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>)  (<a class="graphic graphic_table graphicRef142506" href="/z/d/graphic/142506.html" rel="external">table 2</a>). The lowest dose of the longer-acting glucocorticoid that achieves adequate adrenal steroid suppression should be used. Combination therapy is very effective for suppressing ACTH and minimizes total glucocorticoid exposure.</p><p>Combined regimens may be particularly helpful in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>In females pursuing pregnancy who need additional suppression of serum progesterone. (See <a class="local">'Fertility'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In males in whom reducing TART size is a goal of care. (See <a class="local">'Screening for testicular adrenal rest tumors'</a> below.)</p><p></p><p class="headingAnchor" id="H1336574240"><span class="h4">Longer-acting glucocorticoids for adherence challenges</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisolone</strong><strong> and </strong><strong>methylprednisolone</strong><strong> (preferred longer-acting agents)</strong> – For individuals with classic 21OHD who have difficulty adhering to three daily doses of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>, we prefer <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>  (<a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">table 1</a>). These longer-acting glucocorticoids are typically administered twice a day with a larger dose in the morning to replace the cortisol deficiency (eg, 3 to 5 mg) and a small dose at bedtime to attenuate the pre-dawn ACTH rise (eg, 1 to 2.5 mg) [<a href="#rid10">10</a>]. We avoid "inverse diurnal rhythm" dosing, in which the larger dose is given at bedtime (eg, methylprednisolone 2 mg upon waking and 5 mg at bedtime); such regimens do not replace the cortisol deficiency well and overtreat during the night.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisone</strong> – <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is a pro-drug that requires hepatic conversion to <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> to be biologically active, and interindividual variability in these kinetics makes prednisone a poor choice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dexamethasone</strong> – In adults with classic 21OHD, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is not preferred. Dexamethasone, a very potent and long-acting glucocorticoid, effectively suppresses ACTH secretion but almost always causes the development of cushingoid features with chronic use [<a href="#rid11">11-14</a>]. Further, bedtime administration of 0.25 to 1 mg does not replace the cortisol deficiency well, although this is the most effective regimen for ACTH suppression. Dexamethasone therapy should be of limited duration and reserved for specific treatment goals (eg, TART shrinkage). (See <a class="local">'Screening for testicular adrenal rest tumors'</a> below.)</p><p></p><p class="headingAnchor" id="H227968674"><span class="h4">Modified-release hydrocortisone (limited availability)</span><span class="headingEndMark"> — </span>Modified-released <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> is authorized for use in adolescents and adults with CAH in regions including the United Kingdom and Europe. In individuals with inadequate adrenal androgen suppression on immediate-release hydrocortisone, modified-release hydrocortisone is a reasonable alternative. The total daily dose is 15 to 25 mg, administered in two divided doses. The first dose is taken upon waking, and the second dose is taken at night immediately prior to sleep. The bedtime dose should be approximately 65 to 75 percent of the total daily dose, with the remainder taken in the morning.</p><p class="headingAnchor" id="H922846109"><span class="h3">Patient safety and counseling</span><span class="headingEndMark"> — </span>For all adults with classic 21OHD, ensuring patient safety is a cornerstone of treatment. At each visit, we counsel patients about the importance of adherence to therapy and the potentially life-threatening risks of cortisol deficiency. We ask about any challenges to adherence and any interim periods of nonadherence. We also provide ongoing counseling about circumstances that require glucocorticoid dose adjustments or emergency treatment with injectable glucocorticoid. We ask patients about interim use of stress-dose or emergency injectable glucocorticoid therapy. Key components of patient education are described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Patient education'</a>.)</p><p>Cortisol deficiency can be life-threatening, and adrenal crisis remains a leading cause of mortality in individuals with classic 21OHD. A study from Sweden of 588 adults with classic 21OHD found approximately a two- to fourfold increase in mortality compared with population norms [<a href="#rid15">15</a>]. The major causes of death were adrenal crisis (42 percent), cardiovascular disease (32 percent), cancer (16 percent), and suicide (10 percent). Mortality was highest among males and patients with the most severe disease.</p><p class="headingAnchor" id="H2480952894"><span class="h4">Stress dosing and emergency precautions</span><span class="headingEndMark"> — </span>As with any form of adrenal insufficiency, patients with classic 21OHD should be provided with sick-day rules for stress dosing, medical alert identification, and injectable <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> hemisuccinate (or other injectable glucocorticoid) for emergencies  (<a class="graphic graphic_table graphicRef78904" href="/z/d/graphic/78904.html" rel="external">table 3</a>). At each visit, we verify that patients always wear or carry a medical alert identifier and have an unexpired emergency glucocorticoid injection kit.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid dose adjustment during acute stress</strong> – An increase in glucocorticoid dose is critical during acute physiologic stress including illness or surgery. Increased glucocorticoid doses are usually <strong>not</strong> needed during routine psychological stress or exercise [<a href="#rid2">2</a>]. A detailed approach to stress-dose glucocorticoid therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Circumstances requiring glucocorticoid dose adjustment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency glucocorticoid injection</strong> – Every patient should have injectable glucocorticoid (eg, 100 mg vials of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>), along with syringes for injection. Patients should keep emergency injection kits in a readily accessible place known to all members of the household. Injectable hydrocortisone should be administered immediately in case of significant physical injury (eg, fracture), inability to retain oral medications due to nausea and vomiting, symptoms of incipient adrenal crisis, or if the patient has reduced consciousness or is found unconscious. A detailed approach to the provision and use of emergency glucocorticoid therapy is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Emergency precautions'</a>.)</p><p></p><p class="headingAnchor" id="H1290785393"><span class="h4">Treatment adherence</span><span class="headingEndMark"> — </span>For individuals with classic 21OHD, lifelong adherence to adrenal hormone therapy is essential for safety. For females, avoidance of hyperandrogenic symptoms can motivate adherence to therapy. In contrast, some males may self-discontinue all treatment for months to years without apparent consequence, as long as they do not suffer a significant intercurrent illness. However, this apparent resilience does not indicate remission of cortisol deficiency, and illness or trauma can still precipitate life-threatening adrenal crisis. In addition, males who are undertreated can develop TARTs, which are difficult to treat and can cause pain and irreversible infertility. (See <a class="local">'Screening for testicular adrenal rest tumors'</a> below.)</p><p class="headingAnchor" id="H478346889"><span class="h2">Additional intervention for persistent symptoms</span><span class="headingEndMark"> — </span>In many adults with classic 21OHD, adequate suppression of adrenal androgen production can be achieved without excessive glucocorticoid exposure. Nonetheless, some females may require additional intervention to manage signs of hyperandrogenism, in part because these signs reflect not only circulating androgen concentrations but also tissue-specific regulation of androgen production and signaling. In some adults with severe disease, high glucocorticoid doses are required to suppress adrenal androgen production and lead to chronic, intractable symptoms of excessive glucocorticoid exposure.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgen excess (females)</strong> – In females with 21OHD, additional intervention may be necessary to manage hyperandrogenic symptoms (eg, hirsutism, acne) or to regulate menstrual function. In such cases, combined oral contraceptives can be used in conjunction with glucocorticoid therapy. Combined oral contraceptives both regulate menstrual function and mediate antiandrogenic effects by raising SHBG. In females with hirsutism, mechanical or topical hair removal methods also can be used. However, we <strong>avoid</strong> <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a> for antiandrogen treatment, as it antagonizes the effect of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> and can cause volume depletion. Fludrocortisone treatment for mineralocorticoid replacement therapy is discussed below, and the management of hirsutism in premenopausal females is reviewed in detail separately. (See <a class="local">'Mineralocorticoid replacement'</a> below and  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive signs and symptoms due to glucocorticoid excess</strong> – For adults with classic 21OHD and significant health deterioration due to chronic, supraphysiologic glucocorticoid treatment, enrollment in a clinical trial may provide access to better tolerated treatment regimens.</p><p></p><p class="bulletIndent1">Although a few cases have been reported of unilateral or bilateral adrenalectomy for severe 21OHD [<a href="#rid16">16-18</a>], we avoid this intervention. The major benefit of adrenalectomy is the immediate elimination of adrenal androgen and progesterone secretion, which allows treatment with lower glucocorticoid doses. However, the reduction in adrenal androgen production may be only temporary with unilateral adrenalectomy. Bilateral adrenalectomy heightens the dependency on glucocorticoid and mineralocorticoid replacement therapy and therefore increases risk of adrenal crisis. Further, adrenalectomy does not always prevent subsequent development of adrenal rest tumors, even in females [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H3170045032"><span class="h2">Mineralocorticoid replacement</span><span class="headingEndMark"> — </span>Although mineralocorticoid replacement needs usually decrease in adulthood, most adults with classic 21OHD require continued mineralocorticoid therapy with <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> [<a href="#rid2">2</a>]. The reduced dose requirement reflects the increases in both dietary sodium intake and mineralocorticoid signaling that occur with progression from infancy to adulthood [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H192197407"><span class="h3">Transition to adult fludrocortisone dose</span><span class="headingEndMark"> — </span>In individuals transitioning from pediatric to adult care, the initial adult <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> dose is determined by the patient's current dose and assessment of blood pressure, serum potassium concentration, and plasma renin activity (PRA). We adjust the pediatric dose as needed based on these assessments, detailed below. (See <a class="local">'Monitoring and dose adjustment'</a> below.)</p><p>In adults with classic 21OHD, a typical <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> dose is 0.05 to 0.2 mg daily [<a href="#rid20">20</a>]. This may be taken once daily or in two divided doses. The dose depends on the severity of mineralocorticoid deficiency and concurrent glucocorticoid therapy. <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a> has greater mineralocorticoid activity than other options for glucocorticoid therapy, so adults on hydrocortisone typically require lower fludrocortisone doses (eg, 0.05 to 0.1 mg daily).</p><p class="headingAnchor" id="H1882974018"><span class="h3">Monitoring and dose adjustment</span><span class="headingEndMark"> — </span>During the transition to adult care or titration of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> therapy, adults with classic 21OHD should be evaluated every three to four months through both clinical and laboratory assessments, and then at least once annually. Optimal mineralocorticoid replacement may enable reduction of the glucocorticoid dose [<a href="#rid21">21,22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical assessment</strong> – Clinical assessments include measurement of seated and upright blood pressure and symptom monitoring. Signs and symptoms of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> undertreatment include salt craving, lightheadedness, chronic fatigue, postural hypotension, and nausea, whereas elevated blood pressure and dependent edema can be evidence of overtreatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory assessment</strong> – Laboratory assessments include measurement of serum potassium and PRA. The goals of <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> treatment are to normalize the serum potassium level and achieve a PRA in the normal reference range. However, if PRA remains elevated in adults who are asymptomatic with a normal potassium level, the fludrocortisone dose should <strong>not</strong> be further increased; in this setting, an increased dose can lead to hypokalemia.</p><p></p><p class="bulletIndent1">Laboratory assessment is essential and should be performed even in asymptomatic individuals. Undertreatment can lead to chronic volume depletion that may be clinically silent and evident only on laboratory testing. Irrespective of whether it causes symptoms, undertreatment results in persistent overproduction of renin and angiotensin II. Angiotensin II can stimulate early steps in the steroidogenic pathway, leading to higher adrenal androgen synthesis [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose adjustment</strong> – We adjust the <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> dose as needed in 0.05 to 0.1 mg increments based on evidence of under- or overtreatment. In adults, once a therapeutic replacement dose is established, the fludrocortisone dose generally remains stable for years. However, further dose adjustments may be needed in the setting of increased salt losses (eg, exposure to warm climates, vigorous exercise) or the development of primary hypertension. These adjustments are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Dose adjustments for increased salt losses or primary hypertension'</a>.)</p><p></p><p class="headingAnchor" id="H2871020273"><span class="h1">FERTILITY AND REPRODUCTIVE HEALTH</span></p><p class="headingAnchor" id="H838818502"><span class="h2">Genetic counseling for all adults</span><span class="headingEndMark"> — </span>All individuals with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) should receive genetic counseling during adolescence and at the transition to adult care. Genetic counseling should be provided to both individuals with CAH and their partners during preconception planning. Patients should understand the autosomal recessive inheritance of CAH, the difference between affected and carrier status, and the carrier frequency in the general population. Based on the incidence of classic 21OHD and an estimated carrier frequency of 2 percent of the population, an individual with classic 21OHD has an approximately 1:120 probability of having a child with classic 21OHD [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H1697271304"><span class="h2">Females</span><span class="headingEndMark"> — </span>For females with classic 21OHD, monthly menses and satisfactory sexual function are goals of care, irrespective of the individual's plans for immediate or long-term fertility. Achievement of these goals requires both optimized glucocorticoid therapy and functional anatomy.</p><p class="headingAnchor" id="H3581073359"><span class="h3">Normalize menstrual function</span><span class="headingEndMark"> — </span>Glucocorticoid under- and overtreatment both can cause menstrual irregularity. If adequate adrenal steroid suppression cannot be achieved without excessive glucocorticoid exposure, combined oral contraceptives might help to regulate menstrual function. Adrenal-derived progesterone, rather than androgens, is the major cause of menstrual irregularity and infertility in females with classic 21OHD.</p><p class="headingAnchor" id="H2420902658"><span class="h3">Achieve functional anatomy</span><span class="headingEndMark"> — </span>Females with classic 21OHD who plan to be sexually active with males typically require reconstructive gynecologic surgery as adolescents or adults. Various vaginoplasty procedures, with or without nerve-sparing clitoroplasty [<a href="#rid1">1,24</a>], may be performed either as an initial procedure or revision of a procedure performed earlier. Females may have a delay in establishing sexual relationships, and sexual function may not be optimal, regardless of previous reconstructive surgery [<a href="#rid25">25</a>]. These issues may require counseling and possibly treatment, including additional surgery and/or a vaginal dilation program. Regular dilation and adequate lubrication are important to reduce the risk of restenosis and dyspareunia.</p><p>In one report of 16 adult females with 21OHD, 15 had undergone reconstructive genital surgery, with 8 of 16 requiring second procedures; most females (12 of 15) who had undergone surgery were considered to have an adequate vaginal introitus for sexual activity [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1820840472"><span class="h3">Fertility</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior to attempted conception</strong> – Prior to attempting pregnancy, females with classic 21OHD should have gynecologic consultation, ideally with a surgeon who can provide initial genital reconstruction surgery or modification of previous surgery if needed. This evaluation also facilitates diagnosis of other conditions that can impair fertility independent of 21OHD (eg, tubular obstruction, endometriosis). (See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Female reproduction'</a>.)</p><p></p><p class="bulletIndent1">Once functional anatomy is achieved, glucocorticoid therapy is intensified to achieve greater suppression of adrenal steroid production. The goal of therapy is to achieve a follicular-phase progesterone concentration &lt;0.6 ng/mL (2 nmol/L). This intensified treatment is generally necessary for at least several months to achieve conception and often requires combination therapy with both immediate-release <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> and a longer-acting glucocorticoid administered at bedtime [<a href="#rid9">9</a>]. (See <a class="local">'Combined regimens for persistent hyperandrogenism'</a> above.)</p><p></p><p class="bulletIndent1">If impaired fertility is evident (eg, inability to conceive after 6 to 12 months), despite regular menses and follicular-phase progesterone at goal, referral to a reproductive or fertility specialist should be offered [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – In females with classic 21OHD, fertility rate is reduced [<a href="#rid27">27-29</a>]. Initial studies found that only 25 percent of females with classic 21OHD and 10 percent of those with severe disease ever attempted to conceive [<a href="#rid9">9</a>]. In contrast, a 2021 study from Sweden found that 40 to 42 percent of females with either nonclassic or "simple virilizing" classic 21OHD had borne children, similar to the general population (45 percent); however, &lt;10 percent of females with severe "salt wasting" classic disease had biological children [<a href="#rid30">30</a>]. Furthermore, in individuals who receive proper treatment and have regular intercourse, pregnancy rates exceed 90 percent. Thus, females with classic 21OHD have normal fertility potential, and the low desire to pursue parenthood appears restricted to those with the most severe disease.</p><p></p><p class="bulletIndent1">Factors that contribute to impaired fertility include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased adrenal-derived progesterone, which unfavorably changes cervical mucus and endometrial function, similar to progestin-only contraceptives</p><p class="bulletIndent2"><span class="glyph">•</span>Anovulation</p><p class="bulletIndent2"><span class="glyph">•</span>Vaginal stenosis, from intrauterine virilization and/or sequelae from prior genital reconstructive surgery</p><p class="bulletIndent2"><span class="glyph">•</span>Psychologic factors</p><p class="bulletIndent2"><span class="glyph">•</span>Ovarian hyperandrogenism secondary to chronic anovulation</p><p class="bulletIndent2"><span class="glyph">•</span>Ovarian adrenal rest tumors</p><p></p><p class="headingAnchor" id="H4101502194"><span class="h3">No role for screening for adrenal rest tumors</span><span class="headingEndMark"> — </span>In females with classic 21OHD, we do <strong>not</strong> screen for adrenal rest tumors. Ovarian adrenal rest tumors appear uncommon in treated females with classic 21OHD, with none found in a systematic evaluation of 13 females [<a href="#rid31">31</a>] and only scattered cases reported in the literature [<a href="#rid19">19,32,33</a>]. The sensitivity of ultrasound and magnetic resonance imaging (MRI) for detecting small ovarian rest tumors is not known, although other androgen-producing tumors of the ovary are difficult to detect with conventional imaging studies. Thus, the true prevalence of ovarian rest tumors may be higher because most of these tumors are identified during surgery or at autopsy. Imaging with 18-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) has been used to identify rest tissue in three females (including one with Nelson syndrome) [<a href="#rid19">19,32,33</a>]; in one case, tumors were only visible after concurrent administration of cosyntropin [<a href="#rid19">19</a>].</p><p>As in males with testicular adrenal rest tumors, the etiology of rest tumors in females appears related to sustained elevations in ACTH due to glucocorticoid undertreatment or nonadherence. However, in females, whether glucocorticoid therapy reduces adrenal rest development and/or size is unknown. In females, adrenal rests may develop in the retroperitoneum, including the ovaries and surrounding structures. They occur primarily in the ovarian tissue and, less often, in the paraovarian/adnexal area.</p><p class="headingAnchor" id="H2780822573"><span class="h2">Males</span></p><p class="headingAnchor" id="H1414898309"><span class="h3">Screening for testicular adrenal rest tumors</span><span class="headingEndMark"> — </span>Adult males with classic 21OHD are at risk for testicular adrenal rest tumors (TARTs). The pathogenesis of TARTs is not known, but they are believed to derive either from ectopic adrenal cortex remnants in the testis or from reprogrammed Leydig stem cells, which differentiate and grow under the influence of chronically elevated corticotropin (ACTH). The mass effect of TARTs increases the intratesticular pressure, impairs blood flow to the normal testis, and hinders outflow of semen. Thus, TARTs can cause infertility through multiple mechanisms. (See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Male reproduction'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – In males with classic 21OHD, testicular ultrasound screening should begin in adolescence to detect TARTs, including once at the time of transition to adult care. Thereafter, we perform a physical examination and/or ultrasound monitoring for TARTs at least annually, with additional evaluation performed whenever a period of glucocorticoid undertreatment is detected through laboratory monitoring. (See <a class="local">'Monitoring and dose adjustment'</a> above.)</p><p></p><p class="bulletIndent1">On physical examination, TARTs are firm, irregular masses originating near the rete testes. They are typically bilateral and can be painful when large. However, masses may be small and not palpable on physical examination. Ultrasonography is the most sensitive method of detection [<a href="#rid11">11,12,34,35</a>].</p><p></p><p class="bulletIndent1">Multiple studies have shown that 30 to 50 percent of adolescent and adult males with classic 21OHD develop TARTs [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The best approach to prevent TARTs is to provide adequate glucocorticoid therapy and to avoid long lapses in treatment. Intensified glucocorticoid treatment is sometimes, but not always, effective for decreasing the size of TARTs, relieving pain, and restoring fertility. Case reports have noted either a decrease in size or even disappearance of testicular masses with a course of supraphysiologic doses of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> or with daytime <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> plus bedtime dexamethasone [<a href="#rid11">11,12</a>]. TART shrinkage typically requires several months of treatment intensification, but side effects from these dexamethasone-containing regimens limits the duration of use.</p><p></p><p class="bulletIndent1">Surgical removal provides good long-term control of TART growth and pain, but as demonstrated in a series of eight patients with TART [<a href="#rid37">37</a>], surgery is unlikely to restore testicular testosterone and sperm production.</p><p></p><p class="bulletIndent1">In the presence of TART(s), an elevated follicle-stimulating hormone (FSH) level indicates testicular injury and is a poor prognostic factor for fertility [<a href="#rid38">38</a>]. (See <a class="local">'Fertility'</a> below.)</p><p></p><p class="headingAnchor" id="H3334246231"><span class="h3">Fertility</span><span class="headingEndMark"> — </span>In males with classic 21OHD, a normal semen analysis is the best evidence of good disease control without overtreatment, and sperm banking is an option for young males who want to preserve their fertility. In males, both elevated and suppressed FSH levels can indicate impaired fertility. In males with TARTs, an elevated FSH level suggests testicular injury. A suppressed FSH (and LH) level reflects inadequate glucocorticoid treatment and leads to impaired spermatogenesis. In some males with gonadotropin suppression, glucocorticoid treatment intensification can restore sperm production.</p><p>Males with classic 21OHD are prone to develop oligospermia and infertility, particularly in the setting of chronic glucocorticoid undertreatment. Undertreatment leads to impaired sperm production for two reasons. First, adrenal-derived androgens suppress gonadotropins, leading to reduced testosterone production from Leydig cells. High adrenal-derived androgens compensate for hypogonadism and maintain male secondary sexual characteristics, creating the false impression that testicular function is normal. Second, roughly one-half of these males develop TARTs. (See <a class="local">'Screening for testicular adrenal rest tumors'</a> above.)</p><p>A study from Germany found abnormal semen analysis in 100 percent of 22 males with classic 21OHD [<a href="#rid39">39</a>]. In a larger study from London of 50 males with classic 21OHD, 48 percent had severe oligospermia, and 59 percent of those who desired fertility required treatment intensification to improve sperm production [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H2351908983"><span class="h2">Pregnancy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid and mineralocorticoid therapy</strong> – Females with classic 21OHD require continued glucocorticoid and mineralocorticoid therapy throughout pregnancy. <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a> and/or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> should be used in combination with <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> [<a href="#rid2">2</a>]. Pregnant females should <strong>not</strong> receive glucocorticoids that cross the placenta (eg, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>). During the first and second trimesters, the preconception glucocorticoid regimen is typically continued if it is well tolerated. If concerning glucocorticoid-related side effects occur, the dose can be moderated, primarily by reducing or eliminating the bedtime dose. During the third trimester, an increase in the glucocorticoid dose (eg, 30 to 50 percent) may be needed.</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> dose does not usually require adjustment during pregnancy, but clinical and laboratory monitoring are needed. The management of adrenal hormone therapy in pregnant individuals with adrenal insufficiency is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Pregnancy and labor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delivery</strong> – Cesarean section is almost always required at delivery due to vaginal inadequacy. At the onset of labor or immediately prior to surgery (if Cesarean section is scheduled), glucocorticoid therapy should be intensified as for surgical stress. Glucocorticoid therapy during labor and delivery in females with adrenal insufficiency is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Pregnancy and labor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Full-term pregnancies can be achieved with delivery of healthy infants who have normal growth and development [<a href="#rid40">40</a>]. Female infants without classic 21OHD are born with typical external genitalia; even when maternal androgen production is not normalized during pregnancy, placental aromatase activity protects the fetal genitalia and brain from excess androgen exposure [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Prenatal diagnosis of 21OHD and prenatal treatment of affected offspring are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Prenatal diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Prenatal therapy'</a>.)</p><p></p><p class="headingAnchor" id="H3661479125"><span class="h1">MONITORING FOR LONG-TERM COMPLICATIONS</span><span class="headingEndMark"> — </span>Adults with classic 21-hydroxylase deficiency (21OHD) require ongoing monitoring to assess for potential long-term complications of 21OHD or its treatment. These individuals have increased risk of low bone density, obesity, insulin resistance, and hypertension. They also frequently report reduced quality of life.</p><p>In addition to routine clinical and laboratory assessments for adrenal hormone therapy, we monitor the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiometabolic risk factors</strong> – Body weight and blood pressure should be measured at least annually. Additional cardiometabolic screening (eg, fasting glucose, glycated hemoglobin, lipid panel) should be performed as for the general adult population [<a href="#rid2">2</a>]. All adults should receive counseling about general lifestyle measures to promote cardiometabolic health. General recommendations for diet, exercise, and screening for diabetes and hyperlipidemia in adults are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5364.html" rel="external">"Healthy diet in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/1761.html" rel="external">"Screening for type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a>.)</p><p></p><p class="bulletIndent1">Whether CAH confers increased cardiometabolic risk in the absence of glucocorticoid overtreatment remains uncertain [<a href="#rid42">42</a>]. Use of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> in particular have been associated with increased risk of obesity and insulin resistance [<a href="#rid43">43,44</a>]. In a meta-analysis of 20 observational studies, individuals with CAH had higher systolic and diastolic blood pressure, insulin resistance, and carotid intimal thickness than individuals without CAH [<a href="#rid45">45</a>]. In individual studies, chronic glucocorticoid therapy in adults with 21OHD has been associated with increased fat mass and body mass index (BMI), particularly in older patients [<a href="#rid46">46,47</a>]. Among adults with classic 21OHD, 35 to 41 percent have obesity [<a href="#rid3">3,48</a>], which has been primarily attributed to glucocorticoid overreplacement. Insulin resistance was found in 29 percent [<a href="#rid3">3</a>] and 38 percent [<a href="#rid48">48</a>] of adults with classic 21OHD in two studies. One study found that females with classic 21OHD have an increased risk of gestational diabetes mellitus, with a reported prevalence of approximately 20 percent compared with an estimated prevalence of 7 to 10 percent in the general population [<a href="#rid46">46,49</a>]. Hypercholesterolemia was found in 46 percent of adults in one study [<a href="#rid3">3</a>], but no differences in serum lipids were found between adults with and without CAH in a subsequent meta-analysis that included this study [<a href="#rid45">45</a>]. Glucocorticoid-sparing treatments in development may provide cardiometabolic benefit [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mental health and quality of life</strong> – At each visit, we query patients about mood, stress, daily function (eg, work performance, energy) and overall quality of life. When possible, treatment teams should be interdisciplinary with inclusion of mental health providers [<a href="#rid2">2</a>]. In adults with 21OHD, avoidance of glucocorticoid overtreatment is critical for optimizing mood, energy, and quality of life.</p><p></p><p class="bulletIndent1">In individuals with classic 21OHD, data on long-term psychologic outcomes are limited and inconsistent [<a href="#rid51">51-54</a>]. One study reported an increase in psychiatric disorders in adults with classic 21OHD [<a href="#rid51">51</a>]. A Swedish series of 253 males with classic 21OHD found an increased prevalence of psychiatric disorders including suicidality and psychotic disorders [<a href="#rid52">52</a>]. However, increased psychiatric morbidity was not evident in individuals with the most severe genotypes and appeared to decline following the introduction of newborn screening, suggesting that early diagnosis and treatment may confer protective effects [<a href="#rid52">52</a>]. In a study of 18 females with 21OHD, social adjustment and self-esteem scores were normal, with no obvious increase in psychiatric disorders [<a href="#rid53">53</a>]. Another study found that aggression did not differ between female adolescents with and without classic CAH [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1">Quality of life is broadly reduced in adults with 21OHD [<a href="#rid3">3,48</a>]. In a report of 151 adults, decreased quality of life was associated with the use of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> treatment (versus <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>) [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone mineral density measurement by dual x-ray absorptiometry</strong> – We perform baseline bone mineral density (BMD) measurement with dual-energy x-ray absorptiometry (DXA) in all patients at age 25 years, the approximate expected age of peak bone accrual [<a href="#rid55">55</a>]. Since lifelong glucocorticoid therapy can impact bone accrual, this baseline measurement is important for interpreting subsequent BMD values. After baseline assessment, we remeasure BMD in adults who have had a prolonged (eg, ≥12 months) exposure to high-dose glucocorticoid treatment (&gt;10 mg/day <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent), who develop other risk factors for bone loss, or who experience an atraumatic fracture. In the absence of these triggers for interim measurement, we remeasure BMD according to age- and sex-based guidelines for the general adult population. (See  <a class="medical medical_review" href="/z/d/html/2046.html" rel="external">"Screening for osteoporosis in postmenopausal women and men"</a>.)</p><p></p><p class="bulletIndent1">All adults with classic 21OHD should follow lifestyle measures for optimizing bone health, including adequate intake of calcium and vitamin D and routine physical activity. Vitamin D deficiency is common in children and adults with classic 21OHD. Vitamin D deficiency and insufficiency were observed in 19 and 42 percent of children, respectively, and in 28 and 40 percent of adults, respectively, in a large natural history study [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'General measures'</a> and  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Calcium and vitamin D'</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"</a>.)</p><p></p><p class="bulletIndent1">In adults with classic 21OHD who are diagnosed with osteoporosis based on BMD measurement or atraumatic fracture, management is the same as for other populations with glucocorticoid-induced osteoporosis. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Candidates for pharmacologic therapy'</a>.)</p><p></p><p class="bulletIndent1">In adults with classic 21OHD, BMD is low compared with healthy individuals. In two large series totaling almost 400 adults (the National Institutes of Health (NIH) natural history study [<a href="#rid48">48</a>] and the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) study [<a href="#rid3">3</a>]), 40 percent of patients who underwent bone densitometry had osteopenia, and 5 to 10 percent had osteoporosis. These cohorts generally comprised young adults, and whether long-term risk of fragility fractures is increased is unknown.</p><p></p><p class="headingAnchor" id="H1020432812"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112671.html" rel="external">"Society guideline links: Classic and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H3319978961"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16935.html" rel="external">"Patient education: Congenital adrenal hyperplasia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1550262201"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transition to adult care</strong> – In individuals with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD), the transition from pediatric to adult care should be carefully planned to help prepare patients for issues that arise postpuberty. (See <a class="local">'Transition from pediatric to adult care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal hormone therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Goals of therapy</strong> – In adults with classic 21OHD, the two major goals of adrenal hormone therapy are to (see <a class="local">'Goals of adrenal hormone therapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Provide adequate glucocorticoid and mineralocorticoid replacement</p><p class="bulletIndent3"><span class="glyph">-</span>Attenuate the production of adrenal-derived steroids through partial suppression of both corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid therapy</strong> – For adults with classic 21OHD, we suggest the short-acting glucocorticoid <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> instead of other glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Hydrocortisone is the least likely to cause cushingoid complications. It is typically administered in three divided doses totaling 15 to 30 mg daily  (<a class="graphic graphic_table graphicRef64138" href="/z/d/graphic/64138.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef142506" href="/z/d/graphic/142506.html" rel="external">table 2</a>). (See <a class="local">'Hydrocortisone (preferred glucocorticoid)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Monitoring</strong> – <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">Hydrocortisone</a> therapy is monitored through both clinical and laboratory assessments. The hydrocortisone dose should be titrated to achieve the lowest dose that provides both adequate cortisol replacement and sufficient suppression of adrenal steroid production. (See <a class="local">'Monitoring and dose adjustment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Combined regimens</strong> – In adults in whom adequate adrenal steroid suppression cannot be achieved with standard <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> regimens, we suggest combination therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Combination therapy entails typical cortisol replacement doses of hydrocortisone (eg, 10 to 25 mg daily) during the day and a very small dose of a longer-acting glucocorticoid at bedtime (eg, 1 to 2 mg <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> or <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>). This strategy suppresses ACTH and minimizes total glucocorticoid exposure. (See <a class="local">'Alternative regimens'</a> above.)</p><p></p><p class="bulletIndent3">Combined regimens may be particularly helpful in females pursuing pregnancy who need additional suppression of serum progesterone and in males in whom reducing testicular adrenal rest tumor (TART) size is a goal of care.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patient safety</strong> – Adults with classic 21OHD should be provided with sick-day rules for glucocorticoid stress dosing, a medical alert identifier, and injectable <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (or other injectable glucocorticoid) for emergency use  (<a class="graphic graphic_table graphicRef78904" href="/z/d/graphic/78904.html" rel="external">table 3</a>). (See <a class="local">'Patient safety and counseling'</a> above and  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults", section on 'Patient education and safety'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mineralocorticoid therapy</strong> – Most adults with classic 21OHD require continued mineralocorticoid replacement with <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>, typically 0.05 to 0.2 mg daily. The dose depends on the severity of mineralocorticoid deficiency and concurrent glucocorticoid therapy. The aim of fludrocortisone treatment is to normalize serum potassium concentration, standing blood pressure, and plasma renin activity (PRA). (See <a class="local">'Mineralocorticoid replacement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility and reproductive health</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TARTs</strong> – In males with 21OHD, ultrasound screening for TARTs should begin during adolescence, including once at the time of transition to adult care. We perform a physical examination and/or ultrasound monitoring for TART at least annually. Intensified glucocorticoid treatment is sometimes, but not always, effective for decreasing the size of TARTs, relieving pain, and restoring fertility. (See <a class="local">'Screening for testicular adrenal rest tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reproductive health</strong> – For females with classic 21OHD, monthly menses and optimized sexual function are goals of care, which require optimized glucocorticoid therapy and functional anatomy tailored to individualized goals, respectively. (See <a class="local">'Females'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fertility</strong> – In males, a normal semen analysis is the best evidence of good disease control without overtreatment, and sperm banking is an option for young males who want to preserve their fertility. (See <a class="local">'Fertility'</a> above.)</p><p></p><p class="bulletIndent2">In females attempting pregnancy, glucocorticoid therapy should be titrated to achieve a follicular-phase progesterone &lt;0.6 ng/mL (2 nmol/L). (See <a class="local">'Fertility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for complications</strong> – Adults with classic 21OHD require ongoing monitoring to assess for potential long-term complications of 21OHD and/or chronic glucocorticoid treatment. (See <a class="local">'Monitoring for long-term complications'</a> above.)</p><p></p><p class="headingAnchor" id="H274533727"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management. Endocr Rev 2022; 43:91.</a></li><li><a class="nounderline abstract_t">Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:4043.</a></li><li><a class="nounderline abstract_t">Arlt W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95:5110.</a></li><li><a class="nounderline abstract_t">Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2013; 98:2645.</a></li><li><a class="nounderline abstract_t">Kruse B, Riepe FG, Krone N, et al. Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life. Exp Clin Endocrinol Diabetes 2004; 112:343.</a></li><li><a class="nounderline abstract_t">Auchus RJ, Quint EH. Adolescents with Disorders of Sex Development (DSD)--Lost in Transition? Horm Metab Res 2015; 47:367.</a></li><li><a class="nounderline abstract_t">Holmes-Walker DJ, Conway GS, Honour JW, et al. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1995; 43:291.</a></li><li><a class="nounderline abstract_t">Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol 2016; 174:601.</a></li><li><a class="nounderline abstract_t">Casteràs A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009; 70:833.</a></li><li><a class="nounderline abstract_t">Caldato MC, Fernandes VT, Kater CE. One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency. Arq Bras Endocrinol Metabol 2004; 48:705.</a></li><li><a class="nounderline abstract_t">Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 1987; 47:664.</a></li><li><a class="nounderline abstract_t">Cutfield RG, Bateman JM, Odell WD. Infertility caused by bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency). Fertil Steril 1983; 40:809.</a></li><li><a class="nounderline abstract_t">Cunnah D, Perry L, Dacie JA, et al. Bilateral testicular tumours in congenital adrenal hyperplasia: a continuing diagnostic and therapeutic dilemma. Clin Endocrinol (Oxf) 1989; 30:141.</a></li><li><a class="nounderline abstract_t">Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1987; 27:635.</a></li><li><a class="nounderline abstract_t">Falhammar H, Frisén L, Norrby C, et al. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99:E2715.</a></li><li><a class="nounderline abstract_t">Gunther DF, Bukowski TP, Ritzén EM, et al. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab 1997; 82:3324.</a></li><li><a class="nounderline abstract_t">Bruining H, Bootsma AH, Koper JW, et al. Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:482.</a></li><li><a class="nounderline abstract_t">Van Wyk JJ, Ritzen EM. The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:2993.</a></li><li><a class="nounderline abstract_t">Crocker MK, Barak S, Millo CM, et al. Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97:E2084.</a></li><li><a class="nounderline abstract_t">Hughes IA. Management of congenital adrenal hyperplasia. Arch Dis Child 1988; 63:1399.</a></li><li><a class="nounderline abstract_t">Lopes LA, Dubuis JM, Vallotton MB, Sizonenko PC. Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia? J Pediatr Endocrinol Metab 1998; 11:733.</a></li><li><a class="nounderline abstract_t">Jansen M, Wit JM, van den Brande JL. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth. Acta Paediatr Scand 1981; 70:229.</a></li><li><a class="nounderline abstract_t">Schaison G, Couzinet B, Gourmelen M, et al. Angiotensin and adrenal steroidogenesis: study of 21-hydroxylase-deficient congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980; 51:1390.</a></li><li><a class="nounderline abstract_t">Premawardhana LD, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997; 46:327.</a></li><li><a class="nounderline abstract_t">Kuhnle U, Bullinger M, Schwarz HP, Knorr D. Partnership and sexuality in adult female patients with congenital adrenal hyperplasia. First results of a cross-sectional quality-of-life evaluation. J Steroid Biochem Mol Biol 1993; 45:123.</a></li><li><a class="nounderline abstract_t">Maher JY, Gomez-Lobo V, Merke DP. The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum. Rev Endocr Metab Disord 2023; 24:71.</a></li><li><a class="nounderline abstract_t">Mulaikal RM, Migeon CJ, Rock JA. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987; 316:178.</a></li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Stikkelbroeck NM, Sweep CG, et al. Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2006; 19:677.</a></li><li><a class="nounderline abstract_t">Hagenfeldt K, Janson PO, Holmdahl G, et al. Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 2008; 23:1607.</a></li><li><a class="nounderline abstract_t">Hirschberg AL, Gidlöf S, Falhammar H, et al. Reproductive and Perinatal Outcomes in Women with Congenital Adrenal Hyperplasia: A Population-based Cohort Study. J Clin Endocrinol Metab 2021; 106:e957.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Hermus AR, Schouten D, et al. Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging. Eur Radiol 2004; 14:1802.</a></li><li><a class="nounderline abstract_t">Tiosano D, Vlodavsky E, Filmar S, et al. Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy. Horm Res Paediatr 2010; 74:223.</a></li><li><a class="nounderline abstract_t">Lila AR, Malhotra G, Sarathi V, et al. Localization of remnant and ectopic adrenal tissues with cosyntropin-stimulated 18F-FDG-PET/CT in a patient with Nelson syndrome with persistent hypercortisolism. J Clin Endocrinol Metab 2010; 95:5172.</a></li><li><a class="nounderline abstract_t">Rutgers JL, Young RH, Scully RE. The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988; 12:503.</a></li><li><a class="nounderline abstract_t">Ashley RA, McGee SM, Isotaolo PA, et al. Clinical and pathological features associated with the testicular tumor of the adrenogenital syndrome. J Urol 2007; 177:546.</a></li><li><a class="nounderline abstract_t">Cabrera MS, Vogiatzi MG, New MI. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3070.</a></li><li><a class="nounderline abstract_t">Claahsen-van der Grinten HL, Otten BJ, Takahashi S, et al. Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. J Clin Endocrinol Metab 2007; 92:612.</a></li><li><a class="nounderline abstract_t">King TF, Lee MC, Williamson EE, Conway GS. Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Clin Endocrinol (Oxf) 2016; 84:830.</a></li><li><a class="nounderline abstract_t">Reisch N, Flade L, Scherr M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009; 94:1665.</a></li><li><a class="nounderline abstract_t">Krone N, Wachter I, Stefanidou M, et al. Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood. Clin Endocrinol (Oxf) 2001; 55:523.</a></li><li><a class="nounderline abstract_t">Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999; 84:930.</a></li><li><a class="nounderline abstract_t">Stewart PM, Biller BM, Marelli C, et al. Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency. J Clin Endocrinol Metab 2016; 101:4843.</a></li><li><a class="nounderline abstract_t">Han TS, Krone N, Willis DS, et al. Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). Eur J Endocrinol 2013; 168:887.</a></li><li><a class="nounderline abstract_t">Han TS, Stimson RH, Rees DA, et al. Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2013; 78:197.</a></li><li><a class="nounderline abstract_t">Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, et al. Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2018; 103:4097.</a></li><li><a class="nounderline abstract_t">Falhammar H, Filipsson H, Holmdahl G, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92:110.</a></li><li><a class="nounderline abstract_t">Stikkelbroeck NM, Oyen WJ, van der Wilt GJ, et al. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003; 88:1036.</a></li><li><a class="nounderline abstract_t">Finkielstain GP, Kim MS, Sinaii N, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2012; 97:4429.</a></li><li><a class="nounderline abstract_t">Moyer VA, U.S. Preventive Services Task Force. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160:414.</a></li><li><a class="nounderline abstract_t">Turcu AF, Auchus RJ. Novel treatment strategies in congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 2016; 23:225.</a></li><li><a class="nounderline abstract_t">Slijper FM, Drop SL, Molenaar JC, de Muinck Keizer-Schrama SM. Long-term psychological evaluation of intersex children. Arch Sex Behav 1998; 27:125.</a></li><li><a class="nounderline abstract_t">Falhammar H, Butwicka A, Landén M, et al. Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99:E554.</a></li><li><a class="nounderline abstract_t">Morgan JF, Murphy H, Lacey JH, Conway G. Long term psychological outcome for women with congenital adrenal hyperplasia: cross sectional survey. BMJ 2005; 330:340.</a></li><li><a class="nounderline abstract_t">Isik RO, Kizilcan Cetin S, Cetinkaya S, et al. Evaluation of aggression level in adolescent girls with classical congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2023; 99:135.</a></li><li><a class="nounderline abstract_t">Chakhtoura Z, Bachelot A, Samara-Boustani D, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2008; 158:879.</a></li></ol></div><div id="topicVersionRevision">Topic 136 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961029" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30272171" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20719839" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837188" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Approach to the patient: the adult with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15239019" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25750080" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adolescents with Disorders of Sex Development (DSD)--Lost in Transition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586597" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26865584" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250265" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761542" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3032693" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6317470" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Infertility caused by bilateral testicular masses secondary to congenital adrenal hyperplasia (21-hydroxylase deficiency).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2612016" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bilateral testicular tumours in congenital adrenal hyperplasia: a continuing diagnostic and therapeutic dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843311" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25279502" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329362" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157995" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fertility and body composition after laparoscopic bilateral adrenalectomy in a 30-year-old female with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843131" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The role of bilateral adrenalectomy in the treatment of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22904181" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of PET/CT with cosyntropin stimulation to identify and localize adrenal rest tissue following adrenalectomy in a woman with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3060026" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9829228" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Should we monitor more closely the dosage of 9 alpha-fluorohydrocortisone in salt-losing congenital adrenal hyperplasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7015786" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7002950" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Angiotensin and adrenal steroidogenesis: study of 21-hydroxylase-deficient congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156043" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8481336" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Partnership and sexuality in adult female patients with congenital adrenal hyperplasia. First results of a cross-sectional quality-of-life evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36399318" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491959" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16789634" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fertility in patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18420648" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33135723" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Reproductive and Perinatal Outcomes in Women with Congenital Adrenal Hyperplasia: A Population-based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15322809" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prevalence of ovarian adrenal rest tumours and polycystic ovaries in females with congenital adrenal hyperplasia: results of ultrasonography and MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20431278" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ovarian adrenal rest tumor in a congenital adrenal hyperplasia patient with adrenocorticotropin hypersecretion following adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131539" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Localization of remnant and ectopic adrenal tissues with cosyntropin-stimulated 18F-FDG-PET/CT in a patient with Nelson syndrome with persistent hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3291624" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222630" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical and pathological features associated with the testicular tumor of the adrenogenital syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443169" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long term outcome in adult males with classic congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17090637" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666213" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258407" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High prevalence of reduced fecundity in men with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11678836" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084573" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27623069" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23520247" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22998134" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30272185" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032717" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629082" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22990093" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424622" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27032061" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Novel treatment strategies in congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9562897" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term psychological evaluation of intersex children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24302749" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15677365" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long term psychological outcome for women with congenital adrenal hyperplasia: cross sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37357735" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation of aggression level in adolescent girls with classical congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390993" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
